| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 84 | 2022 | 1203 | 5.310 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 42 | 2019 | 469 | 3.510 |
Why?
|
| Colorectal Neoplasms | 71 | 2022 | 3583 | 2.820 |
Why?
|
| Anus Neoplasms | 17 | 2022 | 412 | 1.750 |
Why?
|
| Colectomy | 15 | 2019 | 289 | 1.690 |
Why?
|
| Adenomatous Polyposis Coli | 21 | 2016 | 221 | 1.600 |
Why?
|
| Adenocarcinoma | 59 | 2022 | 7793 | 1.600 |
Why?
|
| Neoplasm Recurrence, Local | 50 | 2022 | 10066 | 1.250 |
Why?
|
| Digestive System Surgical Procedures | 9 | 2017 | 275 | 1.160 |
Why?
|
| Colonic Neoplasms | 18 | 2016 | 1390 | 0.950 |
Why?
|
| DNA Mismatch Repair | 8 | 2019 | 268 | 0.900 |
Why?
|
| Neoplastic Syndromes, Hereditary | 7 | 2019 | 221 | 0.790 |
Why?
|
| Neoadjuvant Therapy | 26 | 2022 | 4980 | 0.740 |
Why?
|
| Microsatellite Repeats | 11 | 2004 | 576 | 0.700 |
Why?
|
| Pelvic Exenteration | 4 | 2007 | 108 | 0.690 |
Why?
|
| Neoplasm Staging | 52 | 2022 | 13672 | 0.640 |
Why?
|
| Middle Aged | 153 | 2021 | 86454 | 0.620 |
Why?
|
| Chemoradiotherapy | 13 | 2022 | 1947 | 0.620 |
Why?
|
| Male | 176 | 2021 | 123290 | 0.590 |
Why?
|
| Aged | 133 | 2021 | 70329 | 0.570 |
Why?
|
| Humans | 243 | 2022 | 262238 | 0.560 |
Why?
|
| Female | 179 | 2021 | 142262 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 2016 | 552 | 0.540 |
Why?
|
| Pelvic Neoplasms | 4 | 2018 | 189 | 0.540 |
Why?
|
| Genetic Testing | 16 | 2022 | 1587 | 0.540 |
Why?
|
| Insurance, Health | 3 | 2007 | 251 | 0.530 |
Why?
|
| Morbidity | 4 | 2014 | 401 | 0.530 |
Why?
|
| Carcinoma | 12 | 2017 | 2583 | 0.530 |
Why?
|
| Adult | 134 | 2021 | 78097 | 0.530 |
Why?
|
| Combined Modality Therapy | 41 | 2017 | 8883 | 0.520 |
Why?
|
| Germ-Line Mutation | 17 | 2019 | 1047 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 18 | 2022 | 5436 | 0.520 |
Why?
|
| Hepatectomy | 4 | 2012 | 1009 | 0.500 |
Why?
|
| Survival Rate | 40 | 2019 | 12236 | 0.500 |
Why?
|
| Postoperative Complications | 18 | 2017 | 5565 | 0.490 |
Why?
|
| Surgeons | 1 | 2021 | 524 | 0.480 |
Why?
|
| Retrospective Studies | 80 | 2022 | 38010 | 0.470 |
Why?
|
| Microsatellite Instability | 5 | 2021 | 400 | 0.470 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 485 | 0.470 |
Why?
|
| Prognosis | 50 | 2019 | 21748 | 0.460 |
Why?
|
| Aged, 80 and over | 65 | 2017 | 29999 | 0.420 |
Why?
|
| Fluorouracil | 18 | 2022 | 1946 | 0.420 |
Why?
|
| Rectum | 9 | 2022 | 468 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2019 | 5541 | 0.370 |
Why?
|
| Follow-Up Studies | 33 | 2019 | 14906 | 0.370 |
Why?
|
| DNA, Neoplasm | 9 | 2016 | 1906 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2022 | 15874 | 0.370 |
Why?
|
| Lymphatic Metastasis | 22 | 2019 | 4847 | 0.340 |
Why?
|
| Mucins | 1 | 2010 | 285 | 0.330 |
Why?
|
| Health Status Indicators | 1 | 2009 | 227 | 0.320 |
Why?
|
| Salvage Therapy | 6 | 2017 | 2056 | 0.320 |
Why?
|
| Liver Neoplasms | 14 | 2017 | 4561 | 0.320 |
Why?
|
| SEER Program | 8 | 2015 | 1000 | 0.300 |
Why?
|
| MutS Homolog 2 Protein | 7 | 2017 | 178 | 0.300 |
Why?
|
| Brachytherapy | 1 | 2014 | 978 | 0.300 |
Why?
|
| Genetic Markers | 4 | 2019 | 972 | 0.300 |
Why?
|
| Ileostomy | 3 | 2018 | 46 | 0.290 |
Why?
|
| Life Style | 2 | 2021 | 615 | 0.290 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2017 | 565 | 0.290 |
Why?
|
| Re-Irradiation | 2 | 2018 | 163 | 0.270 |
Why?
|
| Colorectal Surgery | 3 | 2016 | 32 | 0.270 |
Why?
|
| Genomic Instability | 3 | 2006 | 520 | 0.270 |
Why?
|
| Intestinal Polyps | 5 | 2002 | 72 | 0.260 |
Why?
|
| DNA-Binding Proteins | 10 | 2017 | 4794 | 0.260 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2006 | 56 | 0.260 |
Why?
|
| Treatment Outcome | 44 | 2022 | 32994 | 0.260 |
Why?
|
| Survivors | 4 | 2017 | 1035 | 0.260 |
Why?
|
| Time Factors | 18 | 2017 | 12968 | 0.260 |
Why?
|
| Duodenal Neoplasms | 4 | 2002 | 138 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 5 | 2003 | 1351 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2017 | 3891 | 0.260 |
Why?
|
| Age Factors | 13 | 2019 | 5387 | 0.250 |
Why?
|
| DNA Sequence, Unstable | 1 | 2004 | 7 | 0.240 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2001 | 37 | 0.240 |
Why?
|
| Perineum | 6 | 2008 | 107 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2015 | 2233 | 0.230 |
Why?
|
| MutL Protein Homolog 1 | 6 | 2019 | 206 | 0.230 |
Why?
|
| Anal Canal | 7 | 2017 | 238 | 0.220 |
Why?
|
| Interleukin-10 | 1 | 2006 | 481 | 0.220 |
Why?
|
| Young Adult | 22 | 2021 | 21478 | 0.220 |
Why?
|
| Capecitabine | 7 | 2019 | 388 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 3987 | 0.210 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 10009 | 0.210 |
Why?
|
| Survival Analysis | 24 | 2018 | 9186 | 0.210 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2005 | 109 | 0.210 |
Why?
|
| Incidence | 13 | 2018 | 5710 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2001 | 2362 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1143 | 0.200 |
Why?
|
| Medical Oncology | 5 | 2014 | 1425 | 0.200 |
Why?
|
| Deoxycytidine | 6 | 2013 | 1361 | 0.200 |
Why?
|
| Adolescent | 29 | 2021 | 31261 | 0.200 |
Why?
|
| Quality of Life | 6 | 2017 | 4580 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 350 | 0.200 |
Why?
|
| Mutation | 15 | 2016 | 15195 | 0.190 |
Why?
|
| Celecoxib | 5 | 2015 | 201 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 406 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 764 | 0.190 |
Why?
|
| Lymph Nodes | 7 | 2011 | 2969 | 0.190 |
Why?
|
| Pathology, Clinical | 1 | 2002 | 152 | 0.190 |
Why?
|
| Sigmoidoscopy | 4 | 2016 | 47 | 0.190 |
Why?
|
| Quality Control | 1 | 2002 | 459 | 0.190 |
Why?
|
| Pedigree | 9 | 2017 | 1889 | 0.190 |
Why?
|
| United States | 20 | 2019 | 15564 | 0.190 |
Why?
|
| Spouses | 1 | 2021 | 134 | 0.190 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2001 | 1064 | 0.180 |
Why?
|
| Risk Assessment | 12 | 2018 | 6892 | 0.180 |
Why?
|
| Lymph Node Excision | 4 | 2019 | 1960 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 590 | 0.180 |
Why?
|
| Parotid Neoplasms | 2 | 1991 | 148 | 0.180 |
Why?
|
| Age of Onset | 8 | 2016 | 826 | 0.180 |
Why?
|
| Base Pair Mismatch | 6 | 2006 | 78 | 0.180 |
Why?
|
| Radiotherapy Dosage | 11 | 2018 | 3847 | 0.170 |
Why?
|
| Chromosome Aberrations | 4 | 2001 | 1958 | 0.170 |
Why?
|
| Radiotherapy | 7 | 2018 | 1826 | 0.170 |
Why?
|
| Insurance Coverage | 2 | 1999 | 256 | 0.170 |
Why?
|
| Enteral Nutrition | 1 | 2001 | 316 | 0.170 |
Why?
|
| Eating | 1 | 2001 | 423 | 0.170 |
Why?
|
| DNA, Satellite | 1 | 1999 | 36 | 0.170 |
Why?
|
| Risk Factors | 21 | 2016 | 17607 | 0.170 |
Why?
|
| Fertility Preservation | 1 | 2021 | 150 | 0.170 |
Why?
|
| Registries | 5 | 2009 | 2187 | 0.170 |
Why?
|
| Pelvis | 4 | 2019 | 366 | 0.170 |
Why?
|
| Adenomatous Polyps | 3 | 2015 | 45 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 13 | 2017 | 3190 | 0.170 |
Why?
|
| Anastomosis, Surgical | 4 | 2013 | 372 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2014 | 436 | 0.160 |
Why?
|
| Ileal Neoplasms | 2 | 1995 | 47 | 0.160 |
Why?
|
| Hepatic Veins | 1 | 1998 | 58 | 0.160 |
Why?
|
| Dissection | 3 | 2003 | 156 | 0.160 |
Why?
|
| Abdominal Neoplasms | 2 | 2005 | 231 | 0.160 |
Why?
|
| Insurance, Life | 1 | 1998 | 3 | 0.160 |
Why?
|
| Mass Screening | 3 | 2019 | 1505 | 0.160 |
Why?
|
| Insurance, Disability | 1 | 1998 | 3 | 0.160 |
Why?
|
| Bile Ducts | 1 | 1998 | 112 | 0.160 |
Why?
|
| Heterozygote | 3 | 2007 | 1018 | 0.160 |
Why?
|
| DNA Repair | 9 | 2010 | 1871 | 0.160 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2009 | 130 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2014 | 170 | 0.150 |
Why?
|
| Neoplasm, Residual | 4 | 2013 | 1668 | 0.150 |
Why?
|
| Intestine, Small | 3 | 2000 | 499 | 0.150 |
Why?
|
| Portal Vein | 2 | 2001 | 356 | 0.150 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 10356 | 0.150 |
Why?
|
| Health Behavior | 1 | 2021 | 603 | 0.150 |
Why?
|
| Cryosurgery | 1 | 1998 | 168 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 2421 | 0.150 |
Why?
|
| Radioimmunodetection | 2 | 1995 | 16 | 0.150 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 47 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 1998 | 374 | 0.140 |
Why?
|
| Medical Errors | 2 | 2015 | 220 | 0.140 |
Why?
|
| Technetium | 2 | 1995 | 77 | 0.140 |
Why?
|
| Prospective Studies | 17 | 2022 | 12914 | 0.140 |
Why?
|
| Cryotherapy | 1 | 1996 | 67 | 0.140 |
Why?
|
| Preoperative Care | 7 | 2013 | 1529 | 0.140 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1996 | 103 | 0.140 |
Why?
|
| Energy Intake | 1 | 2019 | 518 | 0.140 |
Why?
|
| Carcinoid Tumor | 1 | 1998 | 280 | 0.140 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2018 | 167 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 21 | 0.140 |
Why?
|
| Jejunal Neoplasms | 1 | 1995 | 34 | 0.140 |
Why?
|
| Multivariate Analysis | 7 | 2012 | 4321 | 0.140 |
Why?
|
| Sex Factors | 6 | 2013 | 2156 | 0.130 |
Why?
|
| Proportional Hazards Models | 8 | 2016 | 5008 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2015 | 200 | 0.130 |
Why?
|
| Prevalence | 4 | 2019 | 3272 | 0.130 |
Why?
|
| Eflornithine | 1 | 2015 | 59 | 0.130 |
Why?
|
| Radiation Injuries | 4 | 2009 | 1412 | 0.130 |
Why?
|
| Tumor Burden | 4 | 2015 | 1992 | 0.130 |
Why?
|
| Fibromatosis, Abdominal | 1 | 1994 | 9 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2021 | 650 | 0.120 |
Why?
|
| Defecation | 1 | 2014 | 59 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 6219 | 0.120 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 1994 | 3 | 0.120 |
Why?
|
| Rectal Diseases | 2 | 2009 | 55 | 0.120 |
Why?
|
| Colonoscopes | 1 | 1994 | 22 | 0.120 |
Why?
|
| Cisplatin | 4 | 2022 | 2433 | 0.120 |
Why?
|
| Precision Medicine | 2 | 2019 | 1158 | 0.120 |
Why?
|
| Occult Blood | 1 | 1994 | 64 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1451 | 0.120 |
Why?
|
| Exosomes | 1 | 2016 | 256 | 0.120 |
Why?
|
| Neoplasm Metastasis | 7 | 2016 | 5121 | 0.120 |
Why?
|
| Intestinal Neoplasms | 2 | 1994 | 189 | 0.110 |
Why?
|
| Diagnosis, Differential | 8 | 2010 | 4756 | 0.110 |
Why?
|
| Polymorphism, Genetic | 5 | 2006 | 1448 | 0.110 |
Why?
|
| Colonic Pouches | 1 | 2013 | 7 | 0.110 |
Why?
|
| Superior Mesenteric Artery Syndrome | 1 | 2013 | 7 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2300 | 0.110 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2013 | 20 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 1230 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 7 | 2007 | 223 | 0.110 |
Why?
|
| Patient Selection | 4 | 2015 | 2059 | 0.110 |
Why?
|
| Computer Communication Networks | 1 | 2013 | 44 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 133 | 0.110 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 1341 | 0.110 |
Why?
|
| Colon | 4 | 2001 | 673 | 0.110 |
Why?
|
| Hydronephrosis | 1 | 1992 | 50 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 4382 | 0.110 |
Why?
|
| Bevacizumab | 3 | 2013 | 939 | 0.100 |
Why?
|
| Bandages | 1 | 1992 | 71 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2017 | 1532 | 0.100 |
Why?
|
| Stomach Neoplasms | 4 | 2017 | 2282 | 0.100 |
Why?
|
| Photochemotherapy | 3 | 2000 | 97 | 0.100 |
Why?
|
| Antibodies, Neoplasm | 1 | 1992 | 258 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 291 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1286 | 0.100 |
Why?
|
| Colonoscopy | 5 | 2016 | 518 | 0.100 |
Why?
|
| Cohort Studies | 10 | 2017 | 9293 | 0.100 |
Why?
|
| Loss of Heterozygosity | 4 | 2001 | 603 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2006 | 1302 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2011 | 38 | 0.100 |
Why?
|
| Nomograms | 1 | 2013 | 314 | 0.100 |
Why?
|
| Bacterial Infections | 3 | 2009 | 478 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 845 | 0.100 |
Why?
|
| New York | 4 | 1996 | 104 | 0.100 |
Why?
|
| Surgical Flaps | 3 | 2008 | 927 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 14302 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 2107 | 0.090 |
Why?
|
| Phenols | 1 | 1991 | 107 | 0.090 |
Why?
|
| Leucovorin | 5 | 2008 | 333 | 0.090 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2002 | 177 | 0.090 |
Why?
|
| Neoplasm Grading | 4 | 2016 | 1748 | 0.090 |
Why?
|
| Adenolymphoma | 1 | 1990 | 27 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2000 | 82 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2014 | 2326 | 0.090 |
Why?
|
| Disclosure | 1 | 2011 | 181 | 0.090 |
Why?
|
| Texas | 5 | 2018 | 6307 | 0.090 |
Why?
|
| Pain, Intractable | 1 | 1991 | 171 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 4902 | 0.090 |
Why?
|
| Anus Diseases | 1 | 2009 | 29 | 0.090 |
Why?
|
| Precancerous Conditions | 2 | 2000 | 1063 | 0.090 |
Why?
|
| Nerve Block | 1 | 1991 | 176 | 0.090 |
Why?
|
| Surgical Mesh | 3 | 2000 | 209 | 0.090 |
Why?
|
| Endosonography | 3 | 2012 | 536 | 0.090 |
Why?
|
| Neoplasms | 7 | 2021 | 15204 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2017 | 2087 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 378 | 0.080 |
Why?
|
| Medical Records | 2 | 2008 | 414 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7727 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 586 | 0.080 |
Why?
|
| Rosaniline Dyes | 3 | 2007 | 108 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 2485 | 0.080 |
Why?
|
| Sacrum | 1 | 2009 | 134 | 0.080 |
Why?
|
| Robotics | 1 | 2012 | 359 | 0.080 |
Why?
|
| Adenoma | 1 | 2013 | 718 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2009 | 132 | 0.080 |
Why?
|
| Sulfonamides | 4 | 2013 | 1826 | 0.080 |
Why?
|
| Rehabilitation Nursing | 1 | 2007 | 9 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 527 | 0.080 |
Why?
|
| Surgical Stomas | 1 | 2007 | 20 | 0.070 |
Why?
|
| Bowen's Disease | 2 | 2000 | 10 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1266 | 0.070 |
Why?
|
| Palliative Care | 5 | 2014 | 2037 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 272 | 0.070 |
Why?
|
| Pain | 3 | 2010 | 1676 | 0.070 |
Why?
|
| Social Adjustment | 1 | 2007 | 114 | 0.070 |
Why?
|
| Access to Information | 1 | 2007 | 65 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 1993 | 680 | 0.070 |
Why?
|
| Research | 1 | 2009 | 420 | 0.070 |
Why?
|
| Paget Disease, Extramammary | 2 | 2000 | 54 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 1090 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2007 | 1166 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 1999 | 4662 | 0.070 |
Why?
|
| Genome, Human | 3 | 2006 | 1866 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2015 | 756 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 673 | 0.070 |
Why?
|
| Sensitivity and Specificity | 8 | 2007 | 4978 | 0.070 |
Why?
|
| Genes, p53 | 3 | 2000 | 1093 | 0.070 |
Why?
|
| Remission Induction | 3 | 2010 | 3577 | 0.070 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4350 | 0.060 |
Why?
|
| Minisatellite Repeats | 1 | 2005 | 51 | 0.060 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1989 | 489 | 0.060 |
Why?
|
| Pain Management | 1 | 2010 | 670 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2005 | 1829 | 0.060 |
Why?
|
| Internet | 1 | 2009 | 712 | 0.060 |
Why?
|
| Colostomy | 3 | 2013 | 70 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2021 | 2801 | 0.060 |
Why?
|
| Interleukin-15 | 1 | 2006 | 185 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2893 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 3262 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 5718 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 3345 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 363 | 0.060 |
Why?
|
| Chemokines | 1 | 2006 | 314 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 115 | 0.060 |
Why?
|
| Population Surveillance | 3 | 2016 | 628 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 454 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2004 | 2671 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2012 | 6105 | 0.060 |
Why?
|
| Polyps | 2 | 1996 | 74 | 0.060 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 277 | 0.060 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2004 | 69 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 560 | 0.060 |
Why?
|
| Age Distribution | 2 | 2015 | 705 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 206 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2006 | 306 | 0.060 |
Why?
|
| Colitis, Ulcerative | 2 | 1996 | 271 | 0.060 |
Why?
|
| Prostatic Neoplasms | 3 | 2007 | 5777 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2010 | 1439 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 3 | 2005 | 828 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 1998 | 208 | 0.060 |
Why?
|
| Genes, APC | 2 | 2005 | 70 | 0.060 |
Why?
|
| Societies, Medical | 3 | 2006 | 1340 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2016 | 2955 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2007 | 1417 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 1997 | 584 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 626 | 0.050 |
Why?
|
| Consensus | 2 | 2018 | 998 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 704 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 1186 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2003 | 176 | 0.050 |
Why?
|
| Video Recording | 2 | 2016 | 267 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1360 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 4868 | 0.050 |
Why?
|
| Netherlands | 1 | 2002 | 83 | 0.050 |
Why?
|
| Alleles | 4 | 2006 | 2436 | 0.050 |
Why?
|
| Neoplasm Proteins | 4 | 2004 | 3237 | 0.050 |
Why?
|
| Logistic Models | 4 | 2013 | 3450 | 0.050 |
Why?
|
| Comorbidity | 1 | 2008 | 2396 | 0.050 |
Why?
|
| Reoperation | 3 | 2013 | 1405 | 0.050 |
Why?
|
| Wound Healing | 4 | 2008 | 810 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2007 | 799 | 0.050 |
Why?
|
| Abscess | 2 | 2008 | 176 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 2633 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 980 | 0.050 |
Why?
|
| Viruses | 2 | 1993 | 160 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 1180 | 0.050 |
Why?
|
| Urinary Bladder Fistula | 1 | 2000 | 13 | 0.050 |
Why?
|
| Rectal Fistula | 1 | 2000 | 6 | 0.050 |
Why?
|
| Risk | 3 | 2014 | 1972 | 0.050 |
Why?
|
| Mitomycin | 1 | 2022 | 208 | 0.050 |
Why?
|
| Recurrence | 4 | 2016 | 4764 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 836 | 0.050 |
Why?
|
| Genes, ras | 1 | 2004 | 667 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 544 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1539 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 285 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2006 | 176 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 405 | 0.040 |
Why?
|
| Isoenzymes | 2 | 2000 | 608 | 0.040 |
Why?
|
| Treatment Failure | 3 | 2008 | 1392 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 2006 | 1123 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 212 | 0.040 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1999 | 38 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 207 | 0.040 |
Why?
|
| Enteritis | 1 | 1999 | 65 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3637 | 0.040 |
Why?
|
| Clinical Chemistry Tests | 1 | 1999 | 12 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 73 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1998 | 246 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 3478 | 0.040 |
Why?
|
| Periodicity | 1 | 1999 | 68 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2000 | 129 | 0.040 |
Why?
|
| Surgical Stapling | 1 | 1998 | 37 | 0.040 |
Why?
|
| Carboplatin | 2 | 2014 | 825 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 1311 | 0.040 |
Why?
|
| Phenotype | 4 | 2004 | 6273 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2000 | 318 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 157 | 0.040 |
Why?
|
| Genotype | 5 | 2006 | 4108 | 0.040 |
Why?
|
| Omentum | 2 | 1999 | 96 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 604 | 0.040 |
Why?
|
| Point Mutation | 1 | 2001 | 769 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2015 | 855 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 290 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2018 | 56 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3129 | 0.040 |
Why?
|
| Leukemia | 2 | 1996 | 1632 | 0.040 |
Why?
|
| Pyrazoles | 4 | 2013 | 1478 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1998 | 330 | 0.040 |
Why?
|
| Gene Expression | 1 | 2006 | 3564 | 0.040 |
Why?
|
| Appendicitis | 1 | 1999 | 169 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 273 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 173 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1999 | 274 | 0.040 |
Why?
|
| Education | 1 | 1997 | 112 | 0.040 |
Why?
|
| China | 1 | 2019 | 611 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 1998 | 220 | 0.040 |
Why?
|
| Disease Progression | 5 | 2013 | 6695 | 0.040 |
Why?
|
| Carrier Proteins | 5 | 2005 | 2023 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2012 | 7573 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 2444 | 0.040 |
Why?
|
| Fissure in Ano | 1 | 1996 | 8 | 0.040 |
Why?
|
| Appendiceal Neoplasms | 1 | 1999 | 234 | 0.040 |
Why?
|
| Child | 8 | 2017 | 29137 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 349 | 0.040 |
Why?
|
| Informed Consent | 1 | 2000 | 419 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 1329 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1995 | 98 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 348 | 0.040 |
Why?
|
| Premedication | 1 | 1996 | 135 | 0.040 |
Why?
|
| Family | 2 | 1997 | 737 | 0.040 |
Why?
|
| Vagina | 1 | 1998 | 319 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2054 | 0.030 |
Why?
|
| Laparotomy | 2 | 1999 | 211 | 0.030 |
Why?
|
| Observer Variation | 2 | 2013 | 672 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Liquid Biopsy | 1 | 2016 | 158 | 0.030 |
Why?
|
| Tegafur | 1 | 1996 | 50 | 0.030 |
Why?
|
| Uracil | 1 | 1996 | 64 | 0.030 |
Why?
|
| Contraindications | 1 | 1996 | 151 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1997 | 1867 | 0.030 |
Why?
|
| Ileum | 1 | 1996 | 166 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 43 | 0.030 |
Why?
|
| Trans-Activators | 2 | 1999 | 1554 | 0.030 |
Why?
|
| Splenectomy | 1 | 1996 | 157 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2015 | 93 | 0.030 |
Why?
|
| Keratins | 2 | 2007 | 330 | 0.030 |
Why?
|
| Antidotes | 1 | 1995 | 28 | 0.030 |
Why?
|
| Polyurethanes | 1 | 2014 | 36 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 409 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 738 | 0.030 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2016 | 94 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1291 | 0.030 |
Why?
|
| Swine | 1 | 1998 | 1552 | 0.030 |
Why?
|
| Hemagglutination Tests | 1 | 1994 | 33 | 0.030 |
Why?
|
| Guaiac | 1 | 1994 | 6 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 1352 | 0.030 |
Why?
|
| Nuclear Proteins | 5 | 2005 | 3319 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2017 | 516 | 0.030 |
Why?
|
| Endonucleases | 1 | 1995 | 178 | 0.030 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2015 | 158 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 1249 | 0.030 |
Why?
|
| Animals | 8 | 2017 | 59540 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2014 | 222 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1995 | 136 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 1328 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 498 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 4554 | 0.030 |
Why?
|
| Matched-Pair Analysis | 2 | 2006 | 103 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1033 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 784 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 600 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2013 | 13 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 384 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 994 | 0.030 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2013 | 7 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 810 | 0.030 |
Why?
|
| Octreotide | 1 | 1993 | 118 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1996 | 353 | 0.030 |
Why?
|
| Proctoscopy | 1 | 2012 | 17 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 1993 | 149 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 388 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1993 | 181 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 142 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1993 | 241 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1998 | 1866 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1996 | 2311 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1516 | 0.030 |
Why?
|
| Telemedicine | 1 | 2018 | 474 | 0.030 |
Why?
|
| DNA Mutational Analysis | 3 | 2005 | 2282 | 0.030 |
Why?
|
| Phenol | 1 | 1991 | 19 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 588 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 1994 | 209 | 0.020 |
Why?
|
| Prostatectomy | 2 | 2007 | 963 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1550 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1992 | 300 | 0.020 |
Why?
|
| Health Personnel | 1 | 2017 | 631 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 1991 | 66 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 928 | 0.020 |
Why?
|
| Tumor Virus Infections | 1 | 1992 | 217 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 1991 | 257 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 649 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 6036 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2001 | 7227 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 65 | 0.020 |
Why?
|
| Stomach | 1 | 1993 | 387 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1291 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 2000 | 4658 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 552 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 902 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2289 | 0.020 |
Why?
|
| Diarrhea | 1 | 1993 | 689 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2213 | 0.020 |
Why?
|
| Aftercare | 1 | 2011 | 261 | 0.020 |
Why?
|
| Proteins | 1 | 1997 | 1958 | 0.020 |
Why?
|
| Research Design | 2 | 2007 | 1562 | 0.020 |
Why?
|
| Intestines | 1 | 1993 | 688 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 502 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5088 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 924 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 896 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3831 | 0.020 |
Why?
|
| Aloe | 1 | 1988 | 6 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1993 | 411 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 452 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1995 | 1653 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 1988 | 46 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2744 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 1992 | 884 | 0.020 |
Why?
|
| Economics, Medical | 1 | 2007 | 15 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 1039 | 0.020 |
Why?
|
| Drainage | 2 | 2003 | 417 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1998 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2007 | 152 | 0.020 |
Why?
|
| Burns | 1 | 1988 | 117 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2006 | 11980 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2234 | 0.020 |
Why?
|
| Lymphoma | 1 | 1996 | 1466 | 0.020 |
Why?
|
| Rectus Abdominis | 1 | 2008 | 100 | 0.020 |
Why?
|
| DNA Damage | 1 | 1995 | 1955 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 242 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 501 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1098 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 704 | 0.020 |
Why?
|
| Genes, bcl-1 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 326 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2006 | 129 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 177 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 1317 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 167 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2002 | 2598 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 446 | 0.020 |
Why?
|
| Mesentery | 1 | 2005 | 72 | 0.020 |
Why?
|
| Cytosine | 1 | 2006 | 140 | 0.020 |
Why?
|
| Reference Values | 2 | 2000 | 1098 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 638 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2005 | 399 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4333 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2007 | 576 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8894 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1993 | 1307 | 0.020 |
Why?
|
| Communication | 1 | 2011 | 882 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7558 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 567 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2118 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 669 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 416 | 0.010 |
Why?
|
| Gene Amplification | 2 | 1998 | 731 | 0.010 |
Why?
|
| Apoptosis | 1 | 1998 | 7608 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 297 | 0.010 |
Why?
|
| Abdomen | 2 | 1997 | 332 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2005 | 430 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 465 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2012 | 1230 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 660 | 0.010 |
Why?
|
| Abdominal Wall | 1 | 2005 | 184 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 835 | 0.010 |
Why?
|
| Adenine | 1 | 2006 | 638 | 0.010 |
Why?
|
| Pyridines | 1 | 2009 | 1245 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 393 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1556 | 0.010 |
Why?
|
| Base Sequence | 2 | 1999 | 4890 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 3891 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 6065 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1995 | 1381 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 1177 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2001 | 100 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 2000 | 42 | 0.010 |
Why?
|
| Biopsy | 2 | 1999 | 3457 | 0.010 |
Why?
|
| Smad5 Protein | 1 | 1999 | 27 | 0.010 |
Why?
|
| Laboratories | 1 | 2001 | 145 | 0.010 |
Why?
|
| Smad1 Protein | 1 | 1999 | 35 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 1388 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 4943 | 0.010 |
Why?
|
| Intestinal Mucosa | 2 | 1998 | 1083 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 34442 | 0.010 |
Why?
|
| International Cooperation | 1 | 2001 | 323 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1999 | 88 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2233 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 1999 | 128 | 0.010 |
Why?
|
| Smad Proteins | 1 | 1999 | 88 | 0.010 |
Why?
|
| Cost Control | 1 | 1999 | 48 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 726 | 0.010 |
Why?
|
| Case Management | 1 | 1999 | 35 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2000 | 243 | 0.010 |
Why?
|
| Dogs | 1 | 2001 | 1153 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3084 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 157 | 0.010 |
Why?
|
| Electrolytes | 1 | 1999 | 68 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 358 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1999 | 173 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 1999 | 129 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 225 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 828 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 2479 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1998 | 60 | 0.010 |
Why?
|
| Liver | 2 | 2001 | 2906 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1999 | 118 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1999 | 558 | 0.010 |
Why?
|
| Methods | 1 | 1998 | 189 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 482 | 0.010 |
Why?
|
| Polyglycolic Acid | 1 | 1997 | 36 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2086 | 0.010 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1999 | 92 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 1998 | 196 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1999 | 231 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 11573 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1999 | 211 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1999 | 310 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1998 | 328 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2002 | 1309 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 21 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 1996 | 226 | 0.010 |
Why?
|
| Haplotypes | 1 | 1998 | 858 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 695 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1996 | 78 | 0.010 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1995 | 2 | 0.010 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1996 | 145 | 0.010 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 155 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 1394 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 1440 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 225 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 248 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 166 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2000 | 987 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 305 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1995 | 411 | 0.010 |
Why?
|
| Digestive System | 1 | 1995 | 114 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1999 | 510 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 948 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2000 | 1154 | 0.010 |
Why?
|
| Groin | 1 | 1994 | 74 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 625 | 0.010 |
Why?
|
| Floxuridine | 1 | 1994 | 38 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1463 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1999 | 1242 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 331 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 1837 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1995 | 330 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1999 | 1151 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 259 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 3554 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 1 | 1992 | 15 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 554 | 0.010 |
Why?
|
| Anemia | 1 | 1999 | 691 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1992 | 39 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 1447 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 767 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 1004 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 697 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1989 | 5099 | 0.010 |
Why?
|
| Length of Stay | 1 | 1999 | 1930 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1995 | 494 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1993 | 311 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 1992 | 202 | 0.010 |
Why?
|
| Genome | 1 | 1995 | 673 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 1247 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2000 | 16256 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1999 | 747 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 2323 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 1066 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1993 | 585 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 2681 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 2817 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1993 | 350 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 1989 | 108 | 0.010 |
Why?
|
| Silver Sulfadiazine | 1 | 1988 | 15 | 0.010 |
Why?
|
| Occlusive Dressings | 1 | 1988 | 14 | 0.010 |
Why?
|
| Ointments | 1 | 1988 | 28 | 0.000 |
Why?
|
| Salicylates | 1 | 1988 | 58 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1988 | 240 | 0.000 |
Why?
|
| Cysts | 1 | 1989 | 197 | 0.000 |
Why?
|
| Gels | 1 | 1988 | 105 | 0.000 |
Why?
|
| Wound Infection | 1 | 1988 | 54 | 0.000 |
Why?
|
| Administration, Topical | 1 | 1988 | 259 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 6109 | 0.000 |
Why?
|
| Infant | 1 | 2000 | 13299 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 2995 | 0.000 |
Why?
|